Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Drug maker Lilly to...

    Drug maker Lilly to invest $850 million in US operations in 2017

    Written by supriya kashyap kashyap Published On 2017-03-27T11:10:41+05:30  |  Updated On 27 March 2017 11:10 AM IST

    Eli Lilly and Co said it would invest $850 million in its U.S. operations this year, and the drug maker signaled it would be willing to spend more if the Trump administration were to overhaul tax laws.


    Lilly said investments would be made in research laboratories and manufacturing sites, mainly for its diabetes products.


    The move comes amid criticism from President Donald Trump about companies manufacturing abroad for U.S. consumers.


    The U.S. administration has threatened an import tax, while Trump has attacked some of the world's biggest companies, prompting many to make promises to invest more in the United States.


    Many companies are also urging Congress to overhaul the U.S. tax system, saying a set of changes Republicans proposed last year including a big cut in the corporate tax rate - will make them more competitive globally and help create U.S. jobs.


    Lilly could invest more in the United States, particularly if the U.S. introduces more favorable tax laws, Chief Executive David Ricks said in a statement.


    "The equitable treatment of foreign earnings, a lower U.S. corporate tax rate, and U.S. innovation incentives similar to the rest of the world will encourage significant investment," Ricks said.


    "The House Republican Blueprint with border adjustability is designed to achieve these priorities," he added.


    Indianapolis-based Lilly, whose earnings growth resumed in 2015 after three years, has been aggressively developing new drugs.


    In January, the drug maker reported better-than-expected fourth-quarter revenue, driven by higher demand for its diabetes drug Humalog as well as newer products.

    David RicksdiabetesDonald Trumpdrug makerEli LillyHouse Republican BlueprintHumalog
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok